Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4074 |
Name | pancreatic adenocarcinoma |
Definition | A pancreatic carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF mutant | Trametinib | pancreatic adenocarcinoma | sensitive | detail... |
BRAF V600E TP53 C176R | Dabrafenib + Trametinib | pancreatic adenocarcinoma | predicted - sensitive | detail... |
MLH1 negative | Pembrolizumab | pancreatic adenocarcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | pancreatic adenocarcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | pancreatic adenocarcinoma | sensitive | detail... |
RET fusion | Selpercatinib | pancreatic adenocarcinoma | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | pancreatic adenocarcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | pancreatic adenocarcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602602 | Phase II | Bevacizumab + Fluorouracil + Oxaliplatin Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Gemcitabine | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT01013649 | Phase II | Erlotinib + Gemcitabine Gemcitabine | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Active, not recruiting | USA | ISR | CAN | BEL | 0 |
NCT01088815 | Phase II | Gemcitabine + Nab-paclitaxel + Vismodegib | Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | Completed | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
NCT01383538 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Saridegib | FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT01420874 | Phase I | EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) | Completed | USA | 0 |
NCT01431794 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Sonidegib | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT01473940 | Phase I | Gemcitabine + Ipilimumab | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01485744 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Sonidegib | LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT01488552 | Phase Ib/II | Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Metformin | Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT01489865 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Veliparib | ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | Unknown status | USA | 0 |
NCT01506973 | Phase Ib/II | Hydroxychloroquine Gemcitabine | A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer | Completed | USA | 0 |
NCT01555489 | Phase II | Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | Terminated | USA | 0 | |
NCT01562899 | Phase II | Binimetinib + Ganitumab | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT01576666 | Phase Ib/II | Buparlisib + Sonidegib | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 0 |
NCT01585805 | Phase II | Veliparib Cisplatin + Gemcitabine | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Active, not recruiting | USA | ISR | CAN | 0 |
NCT01586611 | Phase III | Gemcitabine Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer | Unknown status | CAN | 0 |
NCT01652976 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Dasatinib | Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT01660971 | Phase I | Dasatinib + Erlotinib + Gemcitabine | Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | Active, not recruiting | USA | 0 |
NCT01666730 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Metformin | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT01683422 | Phase II | Capecitabine + Erlotinib + Gemcitabine | Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer | Terminated | USA | 0 |
NCT01764477 | Phase I | Gemcitabine + PRI-724 | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT01783171 | Phase I | Dinaciclib + MK2206 | Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery | Completed | USA | CAN | 0 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01804530 | Phase I | PLX7486 Gemcitabine + Nab-paclitaxel | Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01825603 | Phase I | ADH-1 + Cisplatin + Gemcitabine | ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01858883 | Phase I | Nab-paclitaxel Filgrastim Itacitinib Gemcitabine | Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT01896869 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Ipilimumab | A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT01908478 | Phase I | Veliparib Gemcitabine | A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer | Completed | USA | 0 |
NCT01921751 | Phase II | Gemcitabine + Nab-paclitaxel Capecitabine | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT01924260 | Phase I | Alisertib + Gemcitabine | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer | Completed | USA | 0 |
NCT01956812 | Phase III | Yttrium Y-90 clivatuzumab tetraxetan Gemcitabine | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1) | Terminated | USA | POL | ISR | FRA | ESP | CAN | BEL | AUT | 0 |
NCT01959672 | Phase II | Nelfinavir Oregovomab Fluorouracil + Leucovorin Gemcitabine | Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT02004262 | Phase II | Irinotecan Erlotinib Cyclophosphamide Capecitabine + Fluorouracil + Gemcitabine | Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting | Completed | USA | CAN | 0 |
NCT02005315 | Phase I | Gemcitabine + Nab-paclitaxel + Vantictumab | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | Completed | USA | 0 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02037230 | Phase Ib/II | Adavosertib + Gemcitabine | Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas | Completed | USA | 0 |
NCT02048384 | Phase Ib/II | Metformin + Sirolimus Metformin | A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | Completed | USA | 0 |
NCT02077881 | Phase Ib/II | Indoximod Gemcitabine + Nab-paclitaxel | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02080260 | Phase II | Regorafenib | A Study of Regorafenib in Advanced Pancreatic Cancer Patients | Completed | USA | 0 |
NCT02117479 | Phase III | Ruxolitinib Capecitabine | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | Terminated | USA | NZL | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 3 |
NCT02119663 | Phase III | Capecitabine Capecitabine + Ruxolitinib | A Study of Ruxolitinib in Pancreatic Cancer Patients | Terminated | USA | SWE | NLD | ISR | IRL | FRA | DNK | CHE | AUT | 5 |
NCT02138383 | Phase I | Enzalutamide Nab-paclitaxel Gemcitabine | Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT02153450 | Phase I | Metformin | Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT02155088 | Phase I | Alpelisib + Gemcitabine + Nab-paclitaxel | BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02178436 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Selinexor | Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02184195 | Phase III | Olaparib | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO) | Completed | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
NCT02194829 | Phase Ib/II | Paclitaxel Gemcitabine Adavosertib | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02227940 | Phase I | Ceritinib + Gemcitabine + Nab-paclitaxel Ceritinib + Cisplatin + Gemcitabine Ceritinib + Gemcitabine | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02231723 | Phase I | Gemcitabine + Nab-paclitaxel + Napabucasin | A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT02243371 | Phase II | GVAX pancreatic cancer vaccine CRS-207 Cyclophosphamide | GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | Completed | USA | 0 |
NCT02244489 | Phase I | Capecitabine Oxaliplatin Momelotinib | Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT02309177 | Phase I | Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | Completed | USA | 0 |
NCT02311361 | Phase I | Durvalumab Tremelimumab | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Completed | USA | 0 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02336087 | Phase I | Gemcitabine + Metformin + Nab-paclitaxel | Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02340117 | Phase II | SGT-53 Gemcitabine + Nab-paclitaxel | Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | Unknown status | USA | 0 |
NCT02349867 | Phase I | Gemcitabine + Nab-paclitaxel + Sorafenib + Vorinostat | Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients | Completed | USA | 0 |
NCT02383433 | Phase II | Gemcitabine + Regorafenib | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | Terminated | USA | 0 |
NCT02399137 | Phase II | Nab-paclitaxel Gemcitabine MM-141 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | Completed | USA | POL | GBR | ESP | DEU | CAN | 0 |
NCT02403271 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02428270 | Phase II | GSK2256098 + Trametinib | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | Completed | CAN | 0 |
NCT02436668 | Phase II | Gemcitabine + Nab-paclitaxel Ibrutinib | Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | 1 |
NCT02446093 | Phase II | AdV-tk + Valacyclovir Acyclovir + AdV-tk | Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (PaTK02) | Active, not recruiting | USA | 1 |
NCT02451982 | Phase Ib/II | Nivolumab Cyclophosphamide + GVAX pancreatic cancer vaccine | Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT02472977 | Phase Ib/II | Nivolumab Ulocuplumab | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | Terminated | USA | FIN | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02562898 | Phase Ib/II | Gemcitabine + Ibrutinib + Paclitaxel | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02570711 | Phase II | Acalabrutinib Gemcitabine + Nab-paclitaxel | Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer | Terminated | USA | 0 |
NCT02574663 | Phase I | Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02575508 | Phase Ib/II | Fluorouracil + Infigratinib + Irinotecan + Oxaliplatin | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT02608229 | Phase I | Gemcitabine + Nab-paclitaxel + Ulixertinib | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | Terminated | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02620423 | Phase I | Gemcitabine Fluorouracil Irinotecan Pelareorep Leucovorin Pembrolizumab | Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT02620800 | Phase Ib/II | Bevacizumab + Fluorouracil + Leucovorin + Nab-paclitaxel + Oxaliplatin | Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02620865 | Phase Ib/II | Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin | Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02639026 | Phase I | Durvalumab + Tremelimumab | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | Completed | USA | 0 |
NCT02648282 | Phase II | Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab | Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02650804 | Phase II | BPM 31510 BPM 31510 + Gemcitabine | BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients | Completed | USA | GBR | 0 |
NCT02651727 | Phase I | Gemcitabine + Nab-paclitaxel + VS-4718 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | Terminated | USA | 0 |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | NZL | GBR | FRA | ESP | AUS | 0 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT02677038 | Phase II | Olaparib | Olaparib in Treating Patients With Stage IV Pancreatic Cancer | Completed | USA | 0 |
NCT02703571 | Phase Ib/II | Ribociclib + Trametinib | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | Terminated | USA | NLD | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02734160 | Phase I | Durvalumab + Galunisertib | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | Completed | USA | ITA | FRA | ESP | 1 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02826486 | Phase II | BKT140 + Pembrolizumab BKT140 | Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT) | Completed | USA | ISR | ESP | 1 |
NCT02847000 | Phase 0 | Decitabine + Tetrahydrouridine | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | Completed | USA | 0 |
NCT02868632 | Phase I | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT02890355 | Phase II | Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Veliparib | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02902484 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Nintedanib Nintedanib | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | Terminated | USA | 0 |
NCT02907099 | Phase II | BKT140 + Pembrolizumab | Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02908451 | Phase I | AbGn-107 | A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer | Terminated | USA | 1 |
NCT02923921 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin Fluorouracil + Leucovorin + Oxaliplatin | Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 2 |
NCT02985125 | Phase Ib/II | Everolimus + Ribociclib | LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | Unknown status | USA | 0 |
NCT03006302 | Phase II | CRS-207 + Epacadostat + Pembrolizumab CRS-207 + Cyclophosphamide + Epacadostat + GVAX pancreatic cancer vaccine + Pembrolizumab | Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer | Completed | USA | 0 |
NCT03086369 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Olaratumab Gemcitabine + Nab-paclitaxel | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | Completed | USA | ESP | DEU | 0 |
NCT03086642 | Phase I | Talimogene laherparepvec | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | Completed | USA | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Completed | USA | 0 |
NCT03098550 | Phase Ib/II | Daratumumab + Nivolumab | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread | Completed | USA | ITA | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS | 2 |
NCT03104439 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Recruiting | USA | 0 |
NCT03122106 | Phase I | Personalized cancer vaccine | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | Terminated | USA | 0 |
NCT03126435 | Phase III | EndoTAG-1 + Gemcitabine Gemcitabine | EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment | Completed | USA | ISR | HUN | FRA | 3 |
NCT03127124 | Phase Ib/II | Bevacizumab + Fluorouracil + Leucovorin + NANT-008 + Oxaliplatin | QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer | Withdrawn | USA | 0 |
NCT03140670 | Phase II | Rucaparib | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy | Terminated | USA | 0 |
NCT03153410 | Phase I | Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab | Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas | Completed | USA | 0 |
NCT03190265 | Phase II | CRS-207 + Ipilimumab + Nivolumab CRS-207 + Cyclophosphamide + GVAX pancreatic cancer vaccine + Ipilimumab + Nivolumab | Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | Completed | USA | 0 |
NCT03192462 | Phase Ib/II | MultiTAA-specific T cells | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (TACTOPS) | Active, not recruiting | USA | 0 |
NCT03213626 | Phase II | Cabozantinib + Erlotinib | Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT03214250 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Nivolumab Gemcitabine + Nab-paclitaxel + Sotigalimab Gemcitabine + Nab-paclitaxel + Nivolumab + Sotigalimab | Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT03245541 | Phase Ib/II | Durvalumab | Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad) | Active, not recruiting | USA | 0 |
NCT03250273 | Phase II | Entinostat + Nivolumab | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT03261947 | Phase II | Simurosertib | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | Completed | USA | 1 |
NCT03269526 | Phase Ib/II | EGFRBi-armed autologous activated T cells | BATs Treatment for Pancreatic Cancer, Phase Ib/II | Active, not recruiting | USA | 0 |
NCT03277209 | Phase I | Plerixafor | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas | Terminated | USA | GBR | 0 |
NCT03281382 | Phase I | Ad5-yCD-mutTKSR39rep-hIL12 | Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT03310632 | Phase Ib/II | Antroquinonol | Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | Active, not recruiting | USA | 2 |
NCT03316599 | Phase I | Ficlatuzumab + Gemcitabine + Nab-paclitaxel | Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT03323944 | Phase I | HuCART-meso cells | CAR T Cell Immunotherapy for Pancreatic Cancer | Recruiting | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03331562 | Phase II | Pembrolizumab Paricalcitol + Pembrolizumab | A SU2C Catalyst Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | Completed | USA | 0 |
NCT03336216 | Phase II | Cabiralizumab + Gemcitabine + Nab-paclitaxel + Nivolumab Cabiralizumab + Nivolumab Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Cabiralizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | Completed | USA | ITA | GBR | ESP | DNK | DEU | CHE | CAN | 3 |
NCT03337087 | Phase Ib/II | Fluorouracil + Leucovorin + Liposomal irinotecan + Rucaparib | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | Active, not recruiting | USA | 0 |
NCT03344172 | Phase II | Avelumab + Gemcitabine + Hydroxychloroquine + Nab-paclitaxel Gemcitabine + Hydroxychloroquine + Nab-paclitaxel | Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer (17-134) | Terminated | USA | 0 |
NCT03368963 | Phase Ib/II | Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Recruiting | USA | 0 |
NCT03373188 | Phase I | Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | Completed | USA | 0 |
NCT03374852 | Phase II | CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | Withdrawn | 0 | |
NCT03376659 | Phase Ib/II | Capecitabine + CV301 + Durvalumab Bevacizumab + Capecitabine + CV301 + Durvalumab | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT03387098 | Phase Ib/II | GI-4000 Leucovorin Nab-paclitaxel Bevacizumab Avelumab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 Oxaliplatin Aldoxorubicin Capecitabine Cyclophosphamide | QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Terminated | USA | 0 |
NCT03403049 | Phase I | Cisplatin + Gemcitabine Capecitabine + Gemcitabine | Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer | Completed | USA | 1 |
NCT03404960 | Phase Ib/II | Ipilimumab + Niraparib Niraparib + Nivolumab | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax) | Completed | USA | 0 |
NCT03410030 | Phase Ib/II | Cisplatin + Gemcitabine + Nab-paclitaxel + Vitamin C | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (AA NABPLAGEM) | Completed | USA | 0 |
NCT03432676 | Phase II | Epacadostat + Pembrolizumab | Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) | Withdrawn | 0 | |
NCT03451773 | Phase Ib/II | Bintrafusp alfa + Gemcitabine | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | Terminated | USA | 0 |
NCT03490760 | Phase II | Durvalumab | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Terminated | USA | 0 |
NCT03504423 | Phase III | CPI-613 CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas | Completed | USA | ISR | FRA | DEU | BEL | 1 |
NCT03507452 | Phase I | BAY2287411 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | Completed | USA | SWE | NLD | GBR | FIN | 0 |
NCT03512756 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 Gemcitabine Fluorouracil Capecitabine | A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer | Terminated | USA | 0 |
NCT03519308 | Phase I | Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol Gemcitabine + Nab-paclitaxel + Nivolumab | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer | Terminated | USA | 0 |
NCT03553004 | Phase II | Niraparib | Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial | Active, not recruiting | USA | 0 |
NCT03563144 | Phase II | Gemcitabine Gemcitabine + Nab-paclitaxel Aldoxorubicin + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Withdrawn | USA | 0 |
NCT03563248 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Nivolumab + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin | Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03586869 | Phase Ib/II | Aldoxorubicin + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Terminated | USA | 0 |
NCT03601923 | Phase II | Niraparib | Niraparib in Patients With Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03611556 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Oleclumab Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study | Completed | USA | NOR | ESP | AUS | 0 |
NCT03649321 | Phase Ib/II | Cisplatin + Gemcitabine + Nab-paclitaxel Bemcentinib + Cisplatin + Gemcitabine + Nab-paclitaxel | Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer | Terminated | USA | 0 |
NCT03665441 | Phase III | Eryaspase + Gemcitabine + Nab-paclitaxel Eryaspase + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1) | Completed | USA | GBR | FRA | 0 |
NCT03666988 | Phase I | GSK3368715 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Terminated | USA | ESP | CAN | AUS | 0 |
NCT03669601 | Phase I | Ceralasertib + Gemcitabine | AZD6738 & Gemcitabine as Combination Therapy (ATRiUM) | Unknown status | GBR | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Active, not recruiting | USA | 0 |
NCT03697564 | FDA approved | Cabiralizumab + Gemcitabine + Nivolumab Gemcitabine | Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). | Suspended | USA | 0 |
NCT03699319 | Phase II | CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT03721744 | Phase II | Gemcitabine + Napabucasin + Paclitaxel Fluorouracil + Liposomal irinotecan Gemcitabine Fluorouracil Capecitabine | A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | Recruiting | FRA | ESP | 1 |
NCT03723915 | Phase II | Pelareorep + Pembrolizumab | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | Terminated | USA | 0 |
NCT03767582 | Phase Ib/II | BMS-813160 + GVAX pancreatic cancer vaccine + Nivolumab BMS-813160 + Nivolumab | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | Recruiting | USA | 0 |
NCT03801915 | Phase II | MVT-5873 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | Completed | USA | 0 |
NCT03816163 | Phase II | Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + Zolbetuximab | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Active, not recruiting | USA | TUR | ITA | IRL | FRA | ESP | BRA | AUS | 5 |
NCT03816358 | Phase Ib/II | Anetumab ravtansine + Gemcitabine + Nivolumab Anetumab ravtansine + Nivolumab Anetumab ravtansine + Ipilimumab + Nivolumab | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ISR | FRA | ESP | CAN | BEL | AUS | 4 |
NCT03851614 | Phase II | Cediranib + Durvalumab Durvalumab + Olaparib | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) | Active, not recruiting | CAN | 0 |
NCT03854110 | Phase Ib/II | Gemcitabine + GP-2250 GP-2250 | Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine | Recruiting | USA | 0 |
NCT03872206 | Phase Ib/II | HPN536 | Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression | Completed | USA | 0 |
NCT03891979 | FDA approved | Ciprofloxacin Metronidazole Pembrolizumab | Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma | Withdrawn | USA | 0 |
NCT03948763 | Phase I | mRNA 5671 mRNA 5671 + Pembrolizumab | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Completed | USA | NZL | AUS | 4 |
NCT03956056 | Phase I | Neoantigen peptide vaccine + Poly ICLC | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | Terminated | USA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03970252 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin | Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | Completed | USA | 0 |
NCT04005690 | Phase II | Olaparib Cobimetinib | Cobimetinib or Olaparib in Treating Patients With Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04034238 | Phase I | LMB-100 + Tofacitinib | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | Completed | USA | 0 |
NCT04050085 | Phase I | Nivolumab + SD-101 | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT04058964 | Phase II | PEGPH20 + Pembrolizumab | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
NCT04083651 | Phase II | Methylnaltrexone Bromide | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | Withdrawn | USA | 0 |
NCT04098081 | Phase II | Galeterone + Gemcitabine Galeterone | 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT04104672 | Phase I | AB680 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies | Recruiting | USA | 0 |
NCT04123574 | Phase I | Talabostat mesylate | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Withdrawn | USA | 0 |
NCT04132505 | Phase I | Binimetinib + Hydroxychloroquine | Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Completed | USA | FRA | ESP | DEU | BEL | 3 |
NCT04137536 | Phase I | EGFRBi-armed autologous activated T cells | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | TUR | CAN | 2 |
NCT04156087 | Phase II | Durvalumab + Gemcitabine + Tremelimumab | Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC) | Completed | BEL | 0 |
NCT04157127 | Phase I | DC tumor cell lysate vaccine | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (DECIST) | Active, not recruiting | USA | 0 |
NCT04172532 | Phase Ib/II | Peposertib | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer | Recruiting | USA | 0 |
NCT04191421 | Phase Ib/II | Siltuximab + Spartalizumab | Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT04193904 | Phase I | MRx0518 | A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer | Terminated | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04214418 | Phase Ib/II | Atezolizumab + Cobimetinib + Hydroxychloroquine | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) | Active, not recruiting | USA | 0 |
NCT04292743 | Phase I | Eryaspase + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT04327986 | Phase Ib/II | Bintrafusp alfa + NHS-IL12 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer | Terminated | USA | 0 |
NCT04331041 | Phase II | Defactinib | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | Recruiting | USA | 0 |
NCT04348045 | Phase II | Durvalumab + Selumetinib Fluorouracil + Irinotecan + Leucovorin Olaparib | Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. (MAZEPPA) | Active, not recruiting | FRA | 0 |
NCT04361162 | Phase II | Ipilimumab + Nivolumab | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04386057 | Phase II | Hydroxychloroquine + LY3214996 LY3214996 | LY3214996 +/- HCQ in Pancreatic Cancer | Completed | USA | 0 |
NCT04387071 | Phase Ib/II | INCAGN01949 + Vidutolimod | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | Terminated | USA | 0 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 1 |
NCT04390763 | Phase II | Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + NIS793 + Spartalizumab Gemcitabine + Nab-paclitaxel + NIS793 | Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1) | Terminated | USA | ITA | GBR | FRA | FIN | ESP | DEU | CZE | CHE | BEL | AUT | AUS | 2 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04404595 | Phase Ib/II | Satricabtagene autoleucel | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | Active, not recruiting | USA | CAN | 0 |
NCT04409002 | Phase II | Dostarlimab-gxly + Niraparib | Niraparib + Dostarlimab + RT in Pancreatic Cancer | Completed | USA | 0 |
NCT04431258 | Phase Ib/II | ABTL0812 + Fluorouracil + Irinotecan + Oxaliplatin Fluorouracil + Irinotecan + Oxaliplatin | ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP) | Completed | USA | ISR | FRA | ESP | 0 |
NCT04514497 | Phase I | Elimusertib + Irinotecan Elimusertib + Topotecan | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04543071 | Phase II | BKT140 + Cemiplimab + Gemcitabine + Nab-paclitaxel | Chemo4METPANC Combination Chemotherapy in Patients With Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT04548752 | Phase II | Olaparib + Pembrolizumab Olaparib | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | Recruiting | USA | 0 |
NCT04616534 | Phase I | Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04666740 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | Active, not recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04683939 | Phase Ib/II | BNT141 BNT141 + Gemcitabine + Nab-paclitaxel | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | Terminated | USA | CAN | 0 |
NCT04731467 | Phase Ib/II | CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | Active, not recruiting | USA | ISR | ESP | 0 |
NCT04787991 | Phase I | Gemcitabine + Ipilimumab + Nab-paclitaxel + Nivolumab Gemcitabine + Hydroxychloroquine + Ipilimumab + Nab-paclitaxel | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION) | Active, not recruiting | USA | 0 |
NCT04807972 | Phase II | ABBV-927 + Budigalimab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin ABBV-927 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis | Terminated | USA | ISR | ESP | AUS | 2 |
NCT04820179 | Phase II | Atezolizumab + Cabozantinib | Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer | Recruiting | USA | 0 |
NCT04825288 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + XB2001 | XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (1-BETTER) | Completed | USA | 0 |
NCT04827953 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + NLM-001 + Zalifrelimab | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 Before Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (NUMANTIA) | Active, not recruiting | ESP | 0 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04940286 | Phase II | Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab | Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04983407 | Phase Ib/II | AVB-S6-500 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel | Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT04999969 | Phase II | AZD0171 + Durvalumab + Gemcitabine + Nab-paclitaxel | Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours | Active, not recruiting | USA | ESP | CAN | 1 |
NCT05000294 | Phase Ib/II | Atezolizumab + Tivozanib | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Recruiting | USA | 0 |
NCT05014776 | Phase II | CRS-207 + Ipilimumab + Pembrolizumab + Tadalafil | A Phase 2 Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT05034627 | Phase I | Calaspargase pegol-mknl + Cobimetinib | Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT05057715 | Phase I | HuCART-meso cells + VCN-01 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05075564 | Phase I | ES002023 | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Unknown status | USA | 0 |
NCT05077800 | Phase II | Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin | FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer | Recruiting | USA | 0 |
NCT05088889 | Phase I | Ipilimumab + Nivolumab | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | Recruiting | ISR | 0 |
NCT05094336 | Phase Ib/II | AMG193 AMG193 + Docetaxel | A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (MTAP) | Recruiting | USA | GBR | FRA | DEU | CHE | CAN | BEL | AUT | AUS | 5 |
NCT05102721 | Phase Ib/II | Avelumab + Pepinemab | Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05109442 | Phase Ib/II | AFM24 + Atezolizumab | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | Recruiting | USA | POL | GBR | ESP | 1 |
NCT05132504 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pembrolizumab | Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT05209074 | Phase I | Fluorouracil + Irinotecan + Ivosidenib + Leucovorin + Oxaliplatin | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05212025 | Phase II | Adavosertib + Gemcitabine | Adavosertib and Gemcitabine in Advanced Pancreatic | Withdrawn | 0 | |
NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Terminated | USA | 0 |
NCT05249101 | Phase Ib/II | Capecitabine Capecitabine + CG200745 | A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05273554 | Phase I | Lenvatinib + Pembrolizumab | A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT05355298 | Phase Ib/II | AMP945 | AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | Recruiting | AUS | 1 |
NCT05365581 | Phase I | ASP2138 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin ASP2138 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab ASP2138 + Paclitaxel + Ramucirumab ASP2138 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | Recruiting | USA | ITA | FRA | 3 |
NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05411133 | Phase I | ARB202 + Atezolizumab ARB202 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | Recruiting | AUS | 1 |
NCT05417386 | Phase I | Fluorouracil + Irinotecan + Leucovorin + NIS793 + Oxaliplatin Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | FOLFIRINOX + NIS793 in Pancreatic Cancer | Terminated | USA | 0 |
NCT05419479 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin AB154 + Sotigalimab + Zimberelimab | Switch Maintenance in Pancreatic | Recruiting | USA | 0 |
NCT05440942 | Phase I | Retifanlimab + Ruxolitinib + Trametinib | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT05451043 | Phase II | Cisplatin + Durvalumab + Gemcitabine + Propranolol + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Propranolol + Tremelimumab Durvalumab + Propranolol + Tremelimumab | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | Recruiting | CAN | 0 |
NCT05451849 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-510 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | 0 |
NCT05462496 | Phase II | Ciprofloxacin + Fluorouracil + Irinotecan + Leucovorin + Metronidazole + Oxaliplatin + Pembrolizumab | Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT05482516 | Phase III | Atezolizumab + Bevacizumab | Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) | Recruiting | USA | 0 |
NCT05482893 | Phase I | PT886 | PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) | Recruiting | USA | 0 |
NCT05484011 | Phase I | CDX-1140 + PGG beta-glucan | A Maintenance Therapy Study of Odetiglucan With a CD40 Agonist (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT05494697 | Phase II | Rintatolimod | Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05518110 | Phase II | Hydroxychloroquine + Trametinib | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer (PaTcH) | Recruiting | IRL | 0 |
NCT05525286 | Phase Ib/II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + SOT102 Gemcitabine + Nab-paclitaxel + SOT102 SOT102 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) | Recruiting | USA | FRA | ESP | CZE | BEL | 0 |
NCT05539430 | Phase I | LB1908 | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05546411 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NIS793 + Oxaliplatin | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | Terminated | USA | 0 |
NCT05586516 | Phase Ib/II | Gemcitabine + IOA-289 + Nab-paclitaxel | A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer | Recruiting | ITA | GBR | 0 |
NCT05604560 | Phase II | SX-682 + Tislelizumab | A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer | Recruiting | USA | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05625412 | Phase I | CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | ARG | 2 |
NCT05632328 | Phase II | Balstilimab + GS-1423 Balstilimab + Gemcitabine + GS-1423 + Nab-paclitaxel | AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer | Recruiting | USA | 0 |
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Terminated | USA | 1 |
NCT05659914 | Phase II | Durvalumab + Olaparib | Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | Active, not recruiting | ESP | 0 |
NCT05673811 | Phase II | Gemcitabine + Nab-paclitaxel + VCN-01 Gemcitabine + Nab-paclitaxel | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer (VIRAGE) | Active, not recruiting | USA | ESP | 0 |
NCT05685602 | Phase I | CA-4948 + Gemcitabine + Nab-paclitaxel | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT05688215 | Phase Ib/II | AB680 + Irinotecan + Leucovorin + Oxaliplatin + Zimberelimab | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05766748 | Phase Ib/II | Azeliragon | Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT05769959 | Phase Ib/II | RO7515629 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Terminated | USA | 0 |
NCT05795595 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | Recruiting | USA | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 1 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05848843 | Phase I | Adagrasib + Durvalumab | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Withdrawn | USA | 0 |
NCT05877599 | Phase I | NT-175 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Recruiting | USA | 0 |
NCT05915351 | Phase II | Enfortumab vedotin-ejfv | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | Recruiting | USA | 0 |
NCT05919537 | Phase Ib/II | Docetaxel + HMBD-001 HMBD-001 Gemcitabine + HMBD-001 + Nab-paclitaxel | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | Recruiting | AUS | 0 |
NCT05926206 | Phase Ib/II | CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas | Withdrawn | USA | 0 |
NCT05985655 | Phase Ib/II | GTAEXS617 | Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) | Recruiting | GBR | BEL | 0 |
NCT05988918 | Phase II | CEP-11981 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | Recruiting | USA | 0 |
NCT06005493 | Phase Ib/II | AZD5863 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | NLD | GBR | FRA | 4 |
NCT06043713 | Phase I | Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Recruiting | USA | 0 |
NCT06078787 | Phase II | Olaparib | Olaparib in PALB2 Advanced Pancreatic Cancer (PALBOLA) | Recruiting | ITA | 0 |
NCT06079346 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Trabedersen | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer (STOP-PC) | Recruiting | USA | 0 |
NCT06094140 | Phase II | Durvalumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer (NEO-IMPACT) | Active, not recruiting | AUS | 0 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06199466 | Phase I | Gemcitabine + Nab-paclitaxel + YL-13027 | A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT06208124 | Phase Ib/II | IMM-6-415 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Recruiting | USA | 0 |
NCT06217666 | Phase I | PCX12 | Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) | Not yet recruiting | USA | 0 |
NCT06218914 | Phase I | NT-112 | A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | Recruiting | USA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
NCT06360354 | Phase I | AMG193 + Cisplatin + Gemcitabine + Pembrolizumab AMG193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AMG193 + Gemcitabine + Nab-paclitaxel | A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion | Recruiting | USA | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 2 |
NCT06387342 | Phase II | CF102 | Namodenoson Treatment of Advanced Pancreatic Cancer | Not yet recruiting | ISR | 0 |
NCT06396091 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Zolbetuximab | A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer | Recruiting | USA | 0 |
NCT06398587 | Phase II | Gemcitabine + Nab-paclitaxel + Onvansertib | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | Withdrawn | USA | 0 |
NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06466187 | Phase I | SGN-MesoC2 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06483555 | Phase Ib/II | Erlotinib + Gemcitabine + Nab-paclitaxel Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel (PANGEA) | Not yet recruiting | USA | 0 |
NCT06560632 | Phase I | Olaparib + RP-3467 RP-3467 | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR) | Recruiting | USA | 0 |